DivestmentApr 14, 2026, 04:47 PM
Assertio Sells Product Franchises to Cosette for $35M Upfront
AI Summary
Assertio Holdings, Inc. completed the sale of its INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP product franchises to Cosette Pharmaceuticals, Inc. The transaction, previously announced on April 8, 2026, involved an upfront cash payment of $35,000,000. The deal also includes potential deferred amounts, such as net sales-based milestone payments of up to $32,000,000 and additional payments related to SPRIX products, including a $1,000,000 payment for successful quality approval and 8% of gross profits from SPRIX through December 31, 2027.
Key Highlights
- Assertio sold INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP product franchises.
- Received $35,000,000 in upfront cash payment from Cosette Pharmaceuticals.
- Potential for up to $32,000,000 in net sales-based milestone payments.
- Additional SPRIX payments include $1M for quality approval and 8% of gross profits.
- Another $2M if SPRIX net sales exceed $7M in calendar year 2027.